Female Health Company (The) (VERU) Director Jesus Socorro Acquires 7,100 Shares

Female Health Company (The) (NASDAQ:VERU) Director Jesus Socorro bought 7,100 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was bought at an average cost of $1.44 per share, with a total value of $10,224.00. Following the transaction, the director now directly owns 7,100 shares in the company, valued at approximately $10,224. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Receive News & Ratings for Female Health Company (The) Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Female Health Company (NASDAQ VERU) traded down 2.74% during midday trading on Friday, hitting $1.42. 54,639 shares of the stock traded hands. Female Health Company has a 1-year low of $0.72 and a 1-year high of $1.51. The company has a 50-day moving average of $1.25 and a 200-day moving average of $1.11.

Female Health Company (The) (NASDAQ:VERU) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.03) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.05. Female Health Company (The) had a negative net margin of 42.02% and a negative return on equity of 16.78%. The firm had revenue of $4.31 million during the quarter, compared to analysts’ expectations of $2.20 million. On average, equities analysts anticipate that Female Health Company will post ($0.17) earnings per share for the current year.

WARNING: “[[title]]” was published by [[site]] and is the property of of [[site]]. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at [[permalink]].

VERU has been the subject of several research analyst reports. HC Wainwright set a $5.00 target price on shares of Female Health Company (The) and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Rodman & Renshaw initiated coverage on shares of Female Health Company (The) in a research report on Wednesday, July 26th. They issued a “buy” rating and a $5.00 target price for the company. Finally, ValuEngine downgraded shares of Female Health Company (The) from a “hold” rating to a “sell” rating in a research report on Friday, July 28th.

About Female Health Company (The)

Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.